+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Radiation Dermatitis - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5306998
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 156 pages
  • DelveInsight

FEATURED COMPANIES

  • BioMimetix JV
This ‘Radiation Dermatitis (RD) - Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of Radiation Dermatitis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Radiation Dermatitis market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Radiation Dermatitis symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Radiation Dermatitis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Radiation Dermatitis Disease Understanding and Treatment Algorithm

Radiation Dermatitis Overview

Radiation dermatitis (also called Radiodermatitis) is a condition caused by radiotherapy (X-Rays) delivered during cancer management. Pathophysiology of radiation dermatitis is a combination of radiation injury and the subsequent inflammatory response and can occur at both the irradiation entrance and exit site. Radiation dermatitis usually begins to occur within 1-4 weeks of treatment and persists for radiation therapy duration. It may require 2-4 weeks to heal after completion of treatment.

Radiation dermatitis (RD) affects nearly 95% of patients who receive radiation for cancer treatment, wherein ~70% of patients have moderate-to-severe skin reactions. Certain treating drugs (termed “radiosensitizers”) combined with radiation therapy can increase incidence and severity of radiation-induced skin reactions by causing increased cellular damage and impaired cellular repair.

Radiation Dermatitis Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Radiation Dermatitis market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Radiation Dermatitis market report gives a thorough understanding of Radiation Dermatitis symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Radiation Dermatitis symptoms of treatment algorithms and treatment guidelines for Radiation Dermatitis symptoms in the US, Europe, and Japan.

Recommendations on using dermatologic skin-care products and practices for the prevention and management of radiation dermatitis are limited: management of RD varies among practitioners. General management of radiation dermatitis begins with basic preventive measures, including self-care and the use of prophylactic topical corticosteroids.

Management of Radiation Dermatitis has two major objectives, prevention of radiation dermatitis (Prophylaxis) and radiation dermatitis treatment. Regarding RD prophylaxis, there was a wide variety of recommendations that include topical agents such as Aloe vera, gentle soap, petroleum-based ointments, topical corticosteroids, sucralfate derivatives, and others. While treating RD, physicians most recommended bland emollients, biafine, calendula, vitamin E, dressing, silver sulfadiazine cream, Topical corticosteroid, and others.

Radiation Dermatitis Epidemiology

The Radiation Dermatitis symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Key Findings

The total incident cases of Radiation Dermatitis are increasing by 7MM during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Radiation Dermatitis symptoms epidemiology segmented as the Radiotherapy Utilization, Incidence of Radiation Dermatitis, Grade-specific cases of Radiation Dermatitis, and Treated cases of Radiation Dermatitis. The report includes Radiation Dermatitis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Radiation Dermatitis Epidemiology

The epidemiology segment also provides the Radiation Dermatitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of incident cases of Radiation Dermatitis associated in 7MM countries was 3,012,048 in 2020.

Radiation Dermatitis Drug Chapters

The Radiation Dermatitis report's drug chapter segment encloses the detailed analysis of Radiation Dermatitis's early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Radiation Dermatitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Radiation Dermatitis Emerging Drug

Tempol (APC-400): Adamis Pharmaceuticals/Matrix Biomed

Tempol, a superoxide dismutase-mimetic drug, has been shown to attenuate radical-induced damage, exerting beneficial effects in the animal models of oxidative stress and hypertension.

BMX-001: BioMimetix JV

BMX-001 (MnTnBuOE-2-PyP5+) is a metalloporphyrin with differential action in response to radiation therapy and chemotherapy-induced oxidative stress. Early preclinical studies demonstrated BMX-001's ability to act as a radioprotectant to healthy tissue such as a central nervous white matter and as a radiosensitizer to cancer cells, in particular, human glioblastoma xenografts.

Radiation Dermatitis Market Outlook

The Radiation Dermatitis market outlook helps build a detailed comprehension of the historical, current, and forecasted Radiation Dermatitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Radiation Dermatitis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the Radiation Dermatitis market in 7MM is expected to grow in the study period 2018-2030.

Despite its prevalence, a gold standard does not exist for its prevention and management. Many of the currently used interventions are often based upon anecdotal evidence or physician preferences. It was observed that use of pharmacological interventions was at a lower end for prevention and treatment of RD as compared to other topical ointments and wound dressing options (Some of the most frequently used wound dressings include hydrocolloid or hydrogel dressings, soft silicone dressings, and silver-based dressings/ointments.). Thus currently, there is a huge gap in the management of RD.

The RD market dynamics are anticipated to change during the forecasted period due to the expected launch of emerging therapies during the forecasted period of 2021-2030. There are presently two pipeline therapies under development for the prevention of Radiation Dermatitis (RD), namely Tempol (Matrix Biomed) and BMX-001 (BioMimetix).

Key Findings

This section includes a glimpse of the Radiation Dermatitis market in the 7MM.

The market size of Radiation Dermatitis in the seven major markets was USD 210.5 million in 2020.

The United States Market Outlook

This section provides the total Radiation Dermatitis market size and market size by therapies in the United States.

The United States accounts for the largest market size of Radiation Dermatitis compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Radiation Dermatitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Radiation Dermatitis market Size and market Size by therapies in Japan are also mentioned.

Radiation Dermatitis Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. The analysis covers the Radiation Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again help investigate factors important in the market uptake and in making financial and regulatory decisions.

Radiation Dermatitis Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Radiation Dermatitis's key players involved in developing targeted therapeutics.

Major players include Adamis Pharmaceuticals/ Matrix Biomed and BioMimetix JV.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Radiation Dermatitis emerging therapies.

Reimbursement Scenario in Radiation Dermatitis

Proactively approaching reimbursement can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Approximately 50-70% of patients with cancer receive radiation therapy as part of their cancer treatment. Radiation therapy can lead to both acute and late side effects. Radiation dermatitis (sometimes referred to as radiation-induced skin reactions or radiation dermatitis) is one of the most reported side effects of radiation therapy and can affect as many as 95% of patients. Radiation dermatitis can have minimal to a significant effect on a patient's quality of life and may also have associated out-of-pocket costs.

All patients who receive radiation therapy are at risk for skin changes, and the severity can vary based on the patient. Nurses are often the first line of contact for patients during radiation therapy and are in an ideal position to guide evidence-based recommendations for interventions to minimize or treat Radiation dermatitis. Clinicians should review their practice to include what works and to eliminate a practice that is not evidence-based.

KOL Views

To keep up with current market trends, we take KOLs' and SMEs' opinions working in the Radiation Dermatitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Radiation Dermatitis market trends. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

The publisher performs a Competitive and Market Intelligence analysis of the Radiation Dermatitis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Radiation Dermatitis, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Radiation Dermatitis epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Radiation Dermatitis is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Radiation Dermatitis market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Radiation Dermatitis market.
Report Highlights
  • In the coming years, the Radiation Dermatitis market is set to change due to the rising awareness of the disease and the favorable environment for new anti-infective modalities, expanding the market's size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Radiation Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Radiation Dermatitis. The launch of emerging therapies will significantly impact the Radiation Dermatitis market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Radiation Dermatitis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Radiation Dermatitis Pipeline Analysis
  • Radiation Dermatitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Radiation Dermatitis Report Key Strengths
  • 10-years Forecast
  • 7MM Coverage
- Radiation Dermatitis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Radiation Dermatitis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered
  • What was the Radiation Dermatitis market share (%) distribution in 2018, and how would it look in 2030?
  • What would be the Radiation Dermatitis total market Size as well as market Size by therapies across the 7MM during the study period (2018-2030)?
  • What are the market's key findings across 7MM, and which country will have the largest Radiation Dermatitis market Size during the study period (2018-2030)?
  • At what CAGR, the Radiation Dermatitis market is expected to grow by 7MM during the study period (2018-2030)?
  • What would be the Radiation Dermatitis market outlook across the 7MM during the study period (2018-2030)?
  • What would be the Radiation Dermatitis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burdens, and unmet needs of Radiation Dermatitis?
  • What is the historical Radiation Dermatitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Radiation Dermatitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Radiation Dermatitis?
  • Out of all 7MM countries, which country would have the largest incident Radiation Dermatitis population during the study period (2018-2030)?
  • At what CAGR is the population expected to grow by 7MM during the study period (2018-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Radiation Dermatitis along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Radiation Dermatitis in the USA, Europe, and Japan?
  • What are the Radiation Dermatitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, and safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Radiation Dermatitis?
  • How many therapies are developed by each company for the treatment of Radiation Dermatitis?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Radiation Dermatitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Radiation Dermatitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Radiation Dermatitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Radiation Dermatitis?
  • What are the global historical and forecasted markets of Radiation Dermatitis?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Radiation Dermatitis market.
  • To understand the future market competition in the Radiation Dermatitis market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Radiation Dermatitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Radiation Dermatitis market.
  • To understand the future market competition in the Radiation Dermatitis market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BioMimetix JV
1 Key Insights

2 Report Introduction

3 Radiation Dermatitis Market Overview at a Glance
3.1 Market Share (%) Distribution of Radiation Dermatitis in 2018
3.2 Market Share (%) Distribution of Radiation Dermatitis in 2030

4 Executive Summary of Radiation Dermatitis

5 Disease Background and Overview
5.1 Introduction
5.2 Pathophysiology
5.3 Signs and Symptoms
5.4 Risk Factors
5.5 Types of Radiation Dermatitis (RD)
5.6 Clinical manifestations
5.7 Diagnosis
5.8 Grading
5.9 Differential Diagnosis
5.1 Treatment
5.10.1 Treatment of acute radiodermatitis
5.10.2 Treatment of chronic radiodermatitis
5.19.1 ONS Treatment Guidelines

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Incident Population of Radiation Dermatitis
6.3 Epidemiology of Radiation Dermatitis
6.4 The United States
6.4.1 Radiotherapy Utilization in the United States
6.4.2 Incidence of Radiation Dermatitis in the United States
6.4.3 Grade-specific cases of Radiation Dermatitis in the United States
6.4.4 Treated cases of Radiation Dermatitis in the United States
6.5 EU5
6.5.1 Germany
6.5.1.1 Radiotherapy Utilization in Germany
6.5.1.2 Incidence of Radiation Dermatitis in Germany
6.5.1.3 Grade-specific cases of Radiation Dermatitis in Germany
6.5.1.4 Treated cases of Radiation Dermatitis in Germany
6.5.2 France
6.5.2.1 Radiotherapy Utilization in France
6.5.2.2 Incidence of Radiation Dermatitis in France
6.5.2.3 Grade-specific cases of Radiation Dermatitis in France
6.5.2.4 Treated cases of Radiation Dermatitis in France
6.5.3 Italy
6.5.3.1 Radiotherapy Utilization in Italy
6.5.3.2 Incidence of Radiation Dermatitis in Italy
6.5.3.3 Grade-specific cases of Radiation Dermatitis in Italy
6.5.3.4 Treated cases of Radiation Dermatitis in Italy
6.5.4 Spain
6.5.4.1 Radiotherapy Utilization in Spain
6.5.4.2 Incidence of Radiation Dermatitis in Spain
6.5.4.3 Grade-specific cases of Radiation Dermatitis in Spain
6.5.4.4 Treated cases of Radiation Dermatitis in Spain
6.5.5 United Kingdom
6.5.5.1 Radiotherapy Utilization in the United Kingdom
6.5.5.2 Incidence of Radiation Dermatitis in the United Kingdom
6.5.5.3 Grade-specific cases of Radiation Dermatitis in the United Kingdom
6.5.5.4 Treated cases of Radiation Dermatitis in the United Kingdom
6.6 Japan
6.6.1 Radiotherapy Utilization in the United States
6.6.2 Incidence of Radiation Dermatitis in Japan
6.6.3 Grade-specific cases of Radiation Dermatitis in Japan
6.6.4 Treated cases of Radiation Dermatitis in Japan

7 Organizations contributing towards Radiation Dermatitis

8 Patient Journey

9 Case Reports

10 Emerging Therapies
10.1 Key Cross Competition
10.2 Tempol (APC-400): Adamis Pharmaceuticals/Matrix Biomed
10.2.1 Drug Description
10.2.2 Regulatory Milestones
10.2.3 Clinical Development
10.2.4 Clinical Trials Information
10.2.5 Safety and Efficacy
10.2.6 Product Profile
10.3 BMX-001: BioMimetix JV
10.3.1 Drug Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Clinical Trials Information
10.3.5 Safety and Efficacy
10.3.6 Product Profile

11 Radiation Dermatitis: Seven Major Market Analysis
13.1 Key Findings
13.2 Market Size of Radiation Dermatitis in 7MM
13.3 Market Outlook
13.4 United States Market Size
11.4.1 Total Market Size of Radiation Dermatitis in the United States
11.4.2 Market Size of Radiation Dermatitis by Therapies in United States
13.5 EU-5 Market Size
11.5.1 Germany
11.5.1.1 Total Market size of Radiation Dermatitis in Germany
11.5.1.2 Market Size of Radiation Dermatitis by Therapies in Germany
11.5.2 France
11.5.2.1 Total Market size of Radiation Dermatitis in France
11.5.2.2 Market Size of Radiation Dermatitis by Therapies in France
11.5.3 Italy
11.5.3.1 Total Market size of Radiation Dermatitis in Italy
11.5.3.2 Market Size of Radiation Dermatitis by Therapies in Italy
11.5.4 Spain
11.5.4.1 Total Market size of Radiation Dermatitis in Spain
11.5.4.2 Market Size of Radiation Dermatitis by Therapies in Spain
11.5.5 United Kingdom
11.5.5.1 Total Market size of Radiation Dermatitis in the United Kingdom
11.5.5.2 Market Size of Radiation Dermatitis by Therapies in the United Kingdom
13.6 Japan
11.6.1 Total Market size of Radiation Dermatitis in Japan
11.6.2 Market Size of Radiation Dermatitis by Therapies in Japan

12 KOL Views

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Unmet Needs

17 Market Access

18 Appendix
20.1 Bibliography
20.2 Report Methodology

19 Publisher Capabilities

20 Disclaimer

21 About the Publisher

List of Tables
Table 1: Summary of Radiation Dermatitis, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Differences between acute and chronic radiation dermatitis
Table 3: Assessment of chronic radiation dermatitis
Table 4: Summary of Recommendations: ONS Guidelines for Radiodermatitis in Patients With Cancer
Table 5: Total Incident Population of Radiation Dermatitis in 7MM in 000s (2018-2030)
Table 6: Radiotherapy Utilization in the United States (2018-2030)
Table 7: Incidence of Radiation Dermatitis in the United States in 000s (2018-2030)
Table 8: Grade-specific cases of Radiation Dermatitis in the United States (2018-2030)
Table 9: Treated cases of Radiation Dermatitis in the United States in 000s (2018-2030)
Table 10: Radiotherapy Utilization in Germany (2018-2030)
Table 11: Incidence of Radiation Dermatitis in Germany (2018-2030)
Table 12: Grade-specific cases of Radiation Dermatitis in Germany (2018-2030)
Table 13: Treated cases of Radiation Dermatitis in Germany (2018-2030)
Table 14: Radiotherapy Utilization in France (2018-2030)
Table 15: Incidence of Radiation Dermatitis in France (2018-2030)
Table 16: Grade-specific cases of Radiation Dermatitis in France (2018-2030)
Table 17: Treated cases of Radiation Dermatitis in France (2018-2030)
Table 18: Radiotherapy Utilization in Italy (2018-2030)
Table 19: Incidence of Radiation Dermatitis in Italy (2018-2030)
Table 20: Grade-specific cases of Radiation Dermatitis in Italy (2018-2030)
Table 21: Treated cases of Radiation Dermatitis in Italy (2018-2030)
Table 22: Radiotherapy Utilization in Spain (2018-2030)
Table 23: Incidence of Radiation Dermatitis in Spain (2018-2030)
Table 24: Grade-specific cases of Radiation Dermatitis in Spain (2018-2030)
Table 25: Treated cases of Radiation Dermatitis in Spain (2018-2030)
Table 26: Radiotherapy Utilization in the United Kingdom (2018-2030)
Table 27: Incidence of Radiation Dermatitis in the United Kingdom (2018-2030)
Table 28: Grade-specific cases of Radiation Dermatitis in the United Kingdom (2018-2030)
Table 29: Treated cases of Radiation Dermatitis in the United Kingdom (2018-2030)
Table 30: Radiotherapy Utilization in Japan (2018-2030)
Table 31: Incidence of Radiation Dermatitis in Japan (2018-2030)
Table 32: Grade-specific cases of Radiation Dermatitis in Japan (2018-2030)
Table 33: Treated cases of Radiation Dermatitis in Japan (2018-2030)
Table 34: Organization contributing to fight against synovial sarcoma
Table 35: Tempol, Clinical Trial Description, 2021
Table 36: BMX-001, Clinical Trial Description, 2021
Table 37: Seven Major Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 38: United States Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 39: United States Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 40: Germany Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 41: Germany Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 42: France Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 43: France Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 44: Italy Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 45: Italy Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 46: Spain Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 47: Spain Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 48: United Kingdom Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 49: United Kingdom Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 50: Japan Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 51: Japan Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)

List of Figures
Figure 1: Mechanisms associated with Radiation Dermatitis: inflammation and oxidative stress.
Figure 2: Total Incident Population of Radiation Dermatitis in 7MM in 000s (2018-2030)
Figure 3: Radiotherapy Utilization in the United States in 000s (2018-2030)
Figure 4: Incidence of Radiation Dermatitis in the United States in 000s (2018-2030)
Figure 5: Grade-specific cases of Radiation Dermatitis in the United States in 000s (2018-2030)
Figure 6: Treated cases of Radiation Dermatitis in the United States in 000s (2018-2030)
Figure 7: Radiotherapy Utilization in Germany in 000s (2018-2030)
Figure 8: Incidence of Radiation Dermatitis in Germany in 000s (2018-2030)
Figure 9: Grade-specific cases of Radiation Dermatitis in Germany in 000s (2018-2030)
Figure 10: Treated cases of Radiation Dermatitis in Germany in 000s (2018-2030)
Figure 11: Radiotherapy Utilization in France in 000s (2018-2030)
Figure 12: Incidence of Radiation Dermatitis in France in 000s (2018-2030)
Figure 13: Grade-specific cases of Radiation Dermatitis in France in 000s (2018-2030)
Figure 14: Treated cases of Radiation Dermatitis in France in 000s (2018-2030)
Figure 15: Radiotherapy Utilization in Italy in 000s (2018-2030)
Figure 16: Incidence of Radiation Dermatitis in Italy in 000s (2018-2030)
Figure 17: Grade-specific cases of Radiation Dermatitis in Italy in 000s (2018-2030)
Figure 18: Treated cases of Radiation Dermatitis in Italy in 000s (2018-2030)
Figure 19: Radiotherapy Utilization in Spain in 000s (2018-2030)
Figure 20: Incidence of Radiation Dermatitis in Spain in 000s (2018-2030)
Figure 21: Grade-specific cases of Radiation Dermatitis in Spain in 000s (2018-2030)
Figure 22: Treated cases of Radiation Dermatitis in Spain in 000s (2018-2030)
Figure 23: Radiotherapy Utilization in the United Kingdom in 000s (2018-2030)
Figure 24: Incidence of Radiation Dermatitis in the United Kingdom in 000s (2018-2030)
Figure 25: Grade-specific cases of Radiation Dermatitis in the United Kingdom in 000s (2018-2030)
Figure 26: Treated cases of Radiation Dermatitis in the United Kingdom in 000s (2018-2030)
Figure 27: Radiotherapy Utilization in Japan in 000s (2018-2030)
Figure 28: Incidence of Radiation Dermatitis in Japan in 000s (2018-2030)
Figure 29: Grade-specific cases of Radiation Dermatitis in Japan in 000s (2018-2030)
Figure 30: Treated cases of Radiation Dermatitis in Japan in 000s (2018-2030)
Figure 31: Tempol’s protection against radiation-induced toxicity
Figure 32: Seven Major Market Size of Radiation Dermatitis in USD Million (2018-2030)
Figure 33: Market Size of Radiation Dermatitis in the United States, USD Million (2018-2030)
Figure 34: The United States Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 35: Market Size of Radiation Dermatitis in Germany, USD Million (2018-2030)
Figure 36: Germany Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 37: Market Size of Radiation Dermatitis in France, USD Million (2018-2030)
Figure 38: France Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 39: Market Size of Radiation Dermatitis in Italy, USD Million (2018-2030)
Figure 40: Italy Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 41: Market Size of Radiation Dermatitis in Spain, USD Million (2018-2030)
Figure 42: Spain Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 43: Market Size of Radiation Dermatitis in the United Kingdom, USD Million (2018-2030)
Figure 44: The United Kingdom Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 45: Market Size of Radiation Dermatitis in Japan, USD Million (2018-2030)
Figure 46: Japan Market Size of Radiation Dermatitis by Therapies in USD Million
Note: Product cover images may vary from those shown
  • Adamis Pharmaceuticals/Matrix Biomed
  • BioMimetix JV
Note: Product cover images may vary from those shown
Adroll
adroll